KJ Muldoon, a 10-month-old baby, was diagnosed with the genetic disease carbamoyl-phosphate synthetase 1 deficiency after he ...

Beam Therapeutics rises after the FDA grants orphan drug status to its gene-editing therapy BEAM-101 for sickle cell disease.

You may have seen it in the news recently: a baby in Pennsylvania with a rare genetic disorder was healed with a personalized ...

The efforts of these heroes and heroines were funded almost entirely by grants from the federal government: the National Institutes of Health, the U.S. National Science Foundation and others. The ...

Forget the hyper-volatile, high-profile stock names. In this environment, lesser-known and less-exciting stocks are apt to ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

Intellia has leveraged its expertise in Crispr/Cas9 gene editing to advance a pipeline of in vivo and ex vivo therapies for diseases with high unmet medical needs. We believe Intellia's proprietary ...

The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.

Princeton University awarded honorary degrees to Omar M. Yaghi, Daniel Chee Tsui, Nancy Weiss Malkiel, Joshua ...

Liberty Science Center’s Genius Gala raised $3.1M to fund STEM education and honored innovators in gene editing, art, tech ...

KJ Muldoon came into the world with a genetic time bomb ticking inside him.

In medical breakthrough, a baby diagnosed with rare genetic disorder is thriving after customized CRISPR gene editing therapy ...